https://stockhub.co/index.php?action=history&feed=atom&title=Hansa_Biopharma_AB Hansa Biopharma AB - Revision history 2026-05-24T11:16:43Z Revision history for this page on the wiki MediaWiki 1.43.5 https://stockhub.co/index.php?title=Hansa_Biopharma_AB&diff=52229&oldid=prev >Paris: Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patie..." 2022-08-16T03:53:13Z <p>Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; == Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company&#039;s lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patie...&quot;</p> <p><b>New page</b></p><div>== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==<br /> <br /> Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company&#039;s lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies&#039; IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.<br /> <br /> == References and notes == <br /> [[Category:Thesis]]<br /> __INDEX__</div> >Paris